Skip to main content
SpringerLink
Log in

T-cell recognition of self peptides as tumor rejection antigens

  • Published:
Immunologic Research Aims and scope Submit manuscript

Abstract

Human melanoma antigens and their epitopes recognized by T cells have recently been identified. HLA-A2 binding epitopes of melanoma antigens MART-1 and gp100 were characterized and suspected to be subdominant/cryptic self determinants. Together with other findings of tumor-specific mutated self peptides as tumor antigens recognized by T cells, the nature of the antitumor immune response to human melanoma has been revealed at a molecular level. These findings have implications not only for understanding of the immune response to self peptides in normal and pathologic conditions, but also for the development of immunotherapies for cancer and autoimmune diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Coulie PG, Lehmann F, Lethe B, Herman J, Lurquin C, Andrawiss M, Boon T: A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci USA 1995;92: 7976–7980.

    Article  PubMed  CAS  Google Scholar 

  2. Wolfel T, Hauer M, Schneider J, Serrano M, Wolfel C, Klehmann-Hieb E, De Plaen E, Hankeln T, zum Buschenfelde K-HM, Beach D: A p16INK-4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995;269:1281–1284.

    Article  PubMed  CAS  Google Scholar 

  3. Kawakami Y, Robbins PF: Genes coding for tumor antigens recognized by T lymphocytes; in DeVita VT, Hellman S, Rosenberg SA (eds): Biologic Therapy of Cancer, ed 2. Philadelphia, Lippincott, 1995, pp 53–64.

    Google Scholar 

  4. Kawakami Y, Robbins PF, Wang R-F, Rosenberg SA: Identification of tumor regression antigens in melanoma. Important Adv Oncol, in press.

  5. Rosenberg SA, Yannelli JR, Yang JC, Tpopalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE: Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1995;86:1159–1166.

    Article  Google Scholar 

  6. Rubin JT, Elwood LJ, Rosenberg SA, Lotze MT: Immunohistochemical correlates of response to recombinant interleukin-2 based immunotherapy in humans. Cancer Res 1989;49:7086–7092.

    PubMed  CAS  Google Scholar 

  7. Pockaj BA, Sherry R, Wei J, Yannelli JR, Carter CS, Leitman SF, Carrasquillo JR, White DE, Steinberg S, Rosenberg SA, Yang JD: Localization of indium-111-labelled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy: Augmentation with cyclophosphamide in association with response. Cancer 1994;73:1731–1737.

    Article  PubMed  CAS  Google Scholar 

  8. Kawakami Y, Zakut R, Topalian SL, Stotter H, Rosenberg SA: Shared human melanoma antigens. Recognition by tumor infiltrating lymphocytes in HLA-A2.1 transfected melanomas. J Immunol 1992;148:638–643.

    PubMed  CAS  Google Scholar 

  9. Anichini A, Maccalli C, Mortarini R, Salvi S, Mazzocchi A, Squarcina P, Herlyn M, Parmiani G: Melanoma cells and normal melanocytes share antigens recognized by HLA-A2 restricted cytotoxic T cell clones from melanoma patients. J Exp Med 1993;177:989–998.

    Article  PubMed  CAS  Google Scholar 

  10. Kawakami Y, Nishimura I, Restifo NP, Topalian SL, O'Neil BH, Shilyansky J, Yannelli JR, Rosenberg SA: T-cell recognition of human melanoma antigens. J Immunother 1993;14:88–93.

    CAS  Google Scholar 

  11. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, Miki T, Rosenberg SA: Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994;91:3515–3519.

    Article  PubMed  CAS  Google Scholar 

  12. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema GJ, Miki T, Rosenberg SA: Identification of a human melanoma antigen recognized by tumor infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994;91:6458–6462.

    Article  PubMed  CAS  Google Scholar 

  13. Kawakami Y, Ellyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JB, Appella E, Rosenberg SA: Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2 restricted tumor infiltrating lymphocytes. J Exp Med 1994;180:347–352.

    Article  PubMed  CAS  Google Scholar 

  14. Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X-Q, Southwood S, Robbins PF, Sette A, Appella E, Rosenberg SA: Recognition of multiple epitopes in the human melanoma antigen gp100 associated with in vivo tumor regression. J Immunol 1995;154:3961–3968.

    PubMed  CAS  Google Scholar 

  15. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee H-G: Allelespecific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1993;351: 290–296.

    Article  Google Scholar 

  16. Hunt DF, Henderson RA, Shabanowitz J, Sakaguchi K, Michel H, Sevilir N, Cox AL, Appella E, Engelhard VH: Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 1992;255:1261–1263.

    Article  PubMed  CAS  Google Scholar 

  17. Parker KC, Shields M, DiBrino M, Brocks A, Coligan JE: Peptide binding to MHC class I molecules: Implications for antigenic peptide prediction. Immunol Res 1995;14:34–57.

    Article  PubMed  CAS  Google Scholar 

  18. Ruppert J, Sidney J, Celis E, Kubo RT, Grey HM, Sette A: Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 1993;74:929–937.

    Article  PubMed  CAS  Google Scholar 

  19. Kast WM, Brandt RMP, Sidney J, Drijfhout J-W, Kubo RT, Grey HM, Melief CJM, Sette A: Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol 1994;152:3904–3912.

    PubMed  CAS  Google Scholar 

  20. Sercarz EE, Lehmann PV, Ametani A, Benichou G, Miller A, Moudgil K: Dominance and crypticity of T cell antigenic determinants. Annu Rev Immunol 1993;11:729–766.

    Article  PubMed  CAS  Google Scholar 

  21. Chen W, Khilko S, Fecondo J, Margulies DH, McClusky J: Determinant selection of major histocompatibility complex class I-restricted antigenic peptides is explained by class I-peptide affinity and is strongly influenced by nondominant anchor residues. J Exp Med 1994;180: 1471–1483.

    Article  PubMed  CAS  Google Scholar 

  22. Moudgil KD, Ametani A, Grewal IS, Kumar V, Sercarz EE: Processing of self-proteins and its impact on shaping the T cell repertoire, auto-immunity and immune regulation. Int Rev Immunol 1993;10:365–377.

    Article  PubMed  CAS  Google Scholar 

  23. Ohno S: ‘Self’ to cytotoxic T cells has to be 1,000 or less high affinity nonapeptides per MHC antigen. Immunogenetics 1992;36:22–27.

    Article  PubMed  CAS  Google Scholar 

  24. Rivoltini L, Kawakami Y, Sakaguchi K, Southwood S, Sette A, Robbins PF, Marincola FM, Salgaller ML, Yannelli JR, Appella E, Rosenberg SA: Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol 1995; 154:2257–2265.

    PubMed  CAS  Google Scholar 

  25. Visseren MJW, van Elsas A, van der Voort EIH, Ressing ME, Kast WM, Schrier PI, Melief CJM: CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells. J Immunol 1995;154:3991–3998.

    PubMed  CAS  Google Scholar 

  26. Van der Bruggen P, Bastin J, Gajewski T, Coulie PG, Boel P, de Smet C, Traversari C, Townsend A, Boon T: A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 1994;24:3038–3043.

    Article  PubMed  Google Scholar 

  27. Elas AV, Nijman HW, Van der Minne CE, Mourer JS, Kast WM, Melief CJM, Schrier PI: Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21 RAS peptide presented by HLA-A2010. Int J Cancer 1995;61: 389–396.

    Article  Google Scholar 

  28. Nijman HW, Houbiers JGA, van der Burg SH, Vierboom MPM, Kenemans P, Kast WM, Melief CJM: Characterization of cytotoxic T lymphocyte epitopes of a self-protein, p53, and a non-self-protein, influenza matrix: Relationship between major histocompatibility complex peptide binding affinity and immune responsiveness to peptides. I. Immunotherapy 1993;14:121–126.

    Article  CAS  Google Scholar 

  29. Houbiers JGA, Nijman HW, van der Burg SH, Drijfhout JW, Kenemans P, van de Velde CJH, Brand A, Momburg F, Kast WM, Melief CJM: In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur J Immunol 1993;23: 2072–2077.

    Article  PubMed  CAS  Google Scholar 

  30. Salgaller M, Marincola F, Rivoltini L, Kawakami Y, Rosenberg SA: Recognition of multiple epitopes in the human melanoma antigen gp100 by antigen specific peripheral blood lymphocytes stimulated with synthetic peptides. Cancer Res 1995;55:4972–4979.

    PubMed  CAS  Google Scholar 

  31. Sensi M, Salvi S, Castelli C, Maccalli C, Mazzocchi A, Mortarini R, Nicolini G, Herlyn M, Parmiani G, Anichini A: T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: Tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone. J Exp Med 1993;178:1231–1246.

    Article  PubMed  CAS  Google Scholar 

  32. Nanda NK, Sercarz EE: Induction of anti-self-immunity to cure cancer. Cell 1995;82:13–17.

    Article  PubMed  CAS  Google Scholar 

  33. Moudgil KD, Sercarz EE: Can antitumor immune responses discriminate between self and nonself? Immunol Today 1994;15:353–355.

    Article  PubMed  CAS  Google Scholar 

  34. Kawakami Y, Rosenberg SA: Immunobiology of human melanoma antigens MART-1 and gp100 and their use of immuno-gene therapy. Int Rev Immunol 1996, in press.

  35. Wang M, Bronte V, Chen PW, Gritz L, Panicali D, Rosenberg SA, Restifo NP: Active immunotherapy of cancer with a nonreplicating recombinant fowipox virus encoding a model tumor-associated antigen. J Immunol 1995;154:4685–4692.

    PubMed  CAS  Google Scholar 

  36. Bronte V, Tsung K, Rao JB, Chen PW, Wang M, Rosenberg SA, Restifo NP: IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J Immunol 1995;154:5282–5292.

    PubMed  CAS  Google Scholar 

  37. Minev B, McFarland BJ, Spiess PJ, Rosenberg SA, Restifo NP: Insertion signal sequence fused to minimal peptides elicits specific CD8+ T-cell responses and prolong survival of thymoma-bearing mice. Cancer Res 1994;54:4155–4161.

    PubMed  CAS  Google Scholar 

  38. Matzinger P: Tolerance, danger, and extended family. Annu Rev Immunol 1994;12:991–1045.

    PubMed  CAS  Google Scholar 

  39. Irvine KR, Rao JB, Rosenberg SA, Restifo NP: Cytokine enhancement of DNA immunization leads to treatment of established pulmonary metastases. J Immunol 1995;156: 238–245.

    Google Scholar 

  40. Udono H, Srivastava PK: Comparison of tumor specific immunogenicities of stress-induced proteins gp96, Hsp90, and Hsp80. J Immunol 1994;152:5398–5403.

    PubMed  CAS  Google Scholar 

  41. Arnold D, Faath S, Rammensee H-G, Schild H: Cross-priming of major histocompability antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96. J Exp Med 1995;182:885–889.

    Article  PubMed  CAS  Google Scholar 

  42. Mottez E, Langlade-Demoyen P, Gournier H, Martinon F, Maryanski J, Kourilsky P, Abastado J-P: Cells expressing a major histocompatibility complex class I molecule with a single covalently bound peptide are highly immunogenic. J Exp Med 1995;181:493–502.

    Article  PubMed  CAS  Google Scholar 

  43. Fisk B, Blevins TL, Wharton JT, Ioannides CG: Icentification of an immunodominant peptide of HER2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocytes lines. J Exp Med 1995;181:2109–2117.

    Article  PubMed  CAS  Google Scholar 

  44. Cheever MA, Disis ML, Bernhard H, Gralow JR, Hand SL, Huseby ES, Qin HL, Takahashi M, Chen W: Immunity to oncogenic proteins. Immunol Rev 1995;145:33–59.

    Article  PubMed  CAS  Google Scholar 

  45. Van Pel A, Van der Bruggen P, Coulie PG, Brichard VG, Lethe B, Van Den Eynde B, Uyttenhove C, Renauld J-C, Boon T: Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol Rev 1995;145:229–250.

    Article  PubMed  Google Scholar 

  46. Van Den Eynde B, Peeters O, De Backar O, Gaugler B, Lucas S, Boon S: A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 1995;182: 689–698.

    Article  PubMed  Google Scholar 

  47. Robbins PF, El-Gamil M, Li YF, Topalian SL, Rivoltini L, Sakaguchi K, Appella E, Kawakami Y, Rosenberg SA: Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24 restricted tumor-infiltrating lymphocytes. J Immunol 1995;154:5944–5950.

    PubMed  CAS  Google Scholar 

  48. Wiedenfeld EA, Fernandez-Vina M, Berzofsky JA, Carbone DP: Evidence for selection against human lung cancers bearing p53 missense mutations which occur within the HLA A-0201 peptide consensus motif. Cancer Res 1994;54:1175–1177.

    PubMed  CAS  Google Scholar 

  49. Chan CC, Palestine AG, Nussenblatt RB: Sympathetic Ophthalmia and Vogt-Koyanagi-Harada Syndrome, in Duane's Clinical Ophthalmology, Philadelphia, Lippincott, 1989.

    Google Scholar 

  50. Wucherpfennig KW, Strominger JL: Molecular mimicry in T cell-mediated autoimmunity: Viral peptides activate human T cell clones specific for myclin basic protein. Cell 1995;80:695–705.

    Article  PubMed  CAS  Google Scholar 

  51. Robbins PF, El-Gamil M, Li YF, Kawakami Y, Loftus D, Appella E, Rosenberg SA: A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 1996;183:1185–1192.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Surgery Branch, National Cancer Institute, National Institutes of Health, Bldg 10, Rm 2B42, 10 Center DR, 20892-1502, Bethesda, Md., USA

    Yutaka Kawakami & Steven A. Rosenberg

Authors
  1. Yutaka Kawakami
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Steven A. Rosenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kawakami, Y., Rosenberg, S.A. T-cell recognition of self peptides as tumor rejection antigens. Immunol Res 15, 179–190 (1996). https://doi.org/10.1007/BF02918248

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02918248

Key Words

Search

Navigation